Obstructive Sleep Apnea of Adult Clinical Trial
— ARCTIC-3Official title:
Multicenter Pilot Study of the Cryosa System for the Treatment of Obstructive Sleep Apnea
Verified date | April 2024 |
Source | Cryosa, Inc. |
Contact | Kristine Selander |
Phone | 763-267-3202 |
kselander[@]cryosa.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic performance of the Cryosa system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | March 31, 2029 |
Est. primary completion date | September 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Age 22 - 70 years 2. Likely suffer moderate to severe OSA based on history and physical or have an established diagnosis of moderate to severe OSA (AHI = 15) based on a prior sleep study. PSG will be performed after enrollment, or an acceptable PSG performed within 3 months of enrollment is required, to verify a) AHI = 15 b) mixed and central apneas total = 25% of apneas, and c) SpO2 must be = 70% for = 90% of sleep time for continued eligibility. 3. Not able to use, refuse to use or intolerant of Positive Airway Pressure (PAP) or Mandibular Advancement Device (MAD) 4. BMI of = 40 kg/m2 at enrollment 5. Is geographically stable and in close proximity to the site 6. Able and willing to provide written consent to participate in the study Exclusion Criteria: 1. Contraindication to general anesthesia or in the opinion of the Investigator would not be able to tolerate the procedure, including intubation during the procedure or in response to an adverse event 2. Severe maxillary mandibular insufficiency that in the opinion of the investigator thought to be the primary cause of OSA 3. Obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction) 4. Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate, or tonsils). 5. Oral cancer or non-healing oral wounds 6. Prior sleep surgeries, including tongue base reduction, UPPP and hypoglossal nerve stimulation. 7. History of radiation therapy to neck or upper respiratory tract 8. Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy) 9. History of cold urticaria 10. History of hospitalization with mechanical ventilation due to COVID-19 per investigator discretion 11. Resistant hypertension defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses 12. Neuromuscular disease or other neurologic deficits (for example multiple sclerosis, muscular dystrophy, Parkinson's disease, transient ischemic attack, epilepsy or cerebrovascular accident) 13. Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD) 14. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism) 15. Untreated, active thyroid disease such as Hashimoto Thyroiditis that may cause angioedema or enlargement of the tongue 16. History of angioedema of the tongue 17. Uncontrolled Diabetes (including Diabetes Mellitus [DM] or Insulin Dependent Diabetes Mellitus [IDDM]) with HbA1c >9. 18. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (< 12 months) myocardial infarction or severe cardiac arrhythmias 19. Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months 20. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months 21. History or current clinical evidence of TIA or stroke or muscular dysfunction 22. Current smoker (= 1 pack/day) 23. Presence of occupational shift work or anticipation of shift changes during the next 2 years 24. Subject has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG and/or HSAT 25. Known active substance use disorder 26. Other severe sleep disorders that in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia/insomnia secondary to chronic pain, PTSD 27. Patients taking any of the following medication that could affect study endpoints: benzodiazepines, Z-drugs (zolpidem and eszopiclone) opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil) 28. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject's ability to meet study requirements and ability to provide study consent 29. Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (= 3 months from treatment date) 30. Any other reason the investigator deems subject is unfit for participation in the study 31. Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing |
Country | Name | City | State |
---|---|---|---|
United States | Albany ENT & Allergy Services | Albany | New York |
United States | Specialty Physician Associates | Bethlehem | Pennsylvania |
United States | University of Tennessee Health Sciences Center | Memphis | Tennessee |
United States | University of Miami | Miami | Florida |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Cryosa, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Home Sleep Apnea Testing (HSAT) - Apnea-Hypopnea Index (AHI4) | Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in AHI4 after treatment compared to baseline. | 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Other | Home Sleep Apnea Testing (HSAT) - Oxygen Desaturation Index (ODI) | Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in ODI sleep metrics after treatment compared to baseline. | 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Other | Home Sleep Apnea Testing (HSAT) - Oxygen Saturation (SpO2) | Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in SpO2 sleep metrics after treatment compared to baseline. | 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Other | Home Sleep Apnea Testing (HSAT) - Hypoxic Burden | Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in hypoxic burden sleep metrics after treatment compared to baseline. | 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Other | Home Sleep Apnea Testing (HSAT) - Snoring | Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in snoring episodes sleep metrics after treatment compared to baseline. | 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Primary | Incidence of Serious Procedure or Device/ Treatment Related Events | Safety will be assessed by evaluating all serious procedure- or device/treatment-related events occurring in the first 90 days post-procedure.
Adverse events (AE), both serious and non-serious, related and unrelated, will be collected from all subjects enrolled for the duration of the study. |
First 90 days post-procedure | |
Secondary | Sleep Testing | Quantify the effect of the Cryosa procedure in reducing the severity of OSA post-procedure by evaluating the change from baseline in the apnea hypopnea index (AHI4) with polysomnography (PSG) testing. | 6 Month Follow-up Visit | |
Secondary | Patient Reported Outcomes (PRO) Efficacy Measures - Epworth Sleepiness Survey (ESS) | Evaluate change in daytime sleepiness after treatment compared to baseline. | 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Secondary | Patient Reported Outcomes (PRO) Efficacy Measures - Functional Outcomes of Sleep Questionnaire (FOSQ) | Evaluate the change of impact of daytime sleepiness on activities of daily living after treatment compared to baseline. | 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Secondary | Patient Reported Outcomes (PRO) Safety Measures - Pain Numeric Scale (NRS) | Evaluate oropharyngeal pain metrics after treatment compared to baseline. | 7 Days, 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure | |
Secondary | Patient Reported Outcomes (PRO) Safety Measures - Eating Assessment Tool (EAT-10) | Evaluate change in swallowing metrics after treatment compared to baseline. | 7 Days, 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05489562 -
Use of Intraoral Suction and Its Effects on Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT05717959 -
Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device
|
N/A | |
Completed |
NCT03940781 -
Effects of Rehabilitation for Patients With Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT03122639 -
Endothelial Function in Obstructive Sleep Apnea
|
Early Phase 1 | |
Recruiting |
NCT05289063 -
Vascular Endothelial Dysfunction in Sleep Apnea
|
Phase 1 | |
Not yet recruiting |
NCT05268471 -
Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea
|
N/A | |
Active, not recruiting |
NCT04864652 -
Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of OSA
|
N/A | |
Enrolling by invitation |
NCT05433883 -
The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness
|
N/A | |
Recruiting |
NCT06103630 -
Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device
|
N/A | |
Recruiting |
NCT06283095 -
Management of Obstructive Sleep Apnea Syndrome by Expansion Palatoplasty
|
N/A | |
Completed |
NCT03156283 -
SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence
|
N/A | |
Completed |
NCT03362385 -
OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients
|
||
Recruiting |
NCT06447818 -
Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome
|
||
Completed |
NCT04643782 -
Comparative Study of the ANNEā¢ One System to Diagnose Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT03463785 -
Does Race Make a Difference in Obstructive Sleep Apnea?
|
||
Recruiting |
NCT03618719 -
Impact of Intermittent Hypoxia on the Function of the Phagocytes
|
||
Completed |
NCT03048604 -
BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)
|
N/A | |
Recruiting |
NCT05290350 -
Long COVID-19 Fatigue and Obstructive Sleep Apnea
|
||
Recruiting |
NCT05739617 -
Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT03980158 -
Change in Tongue Strength and Fatigue After Upper Airway Stimulation Therapy
|